Clinical trials: Amyotrophic Lateral Sclerosis, open to volunteers
Amyotrophic Lateral Sclerosis
ASSESS ALL ALS Study
The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control…
- Trial name
- NCT06578195
- Where
- 37 sites in United States, Puerto Rico
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
ALS (Amyotrophic Lateral Sclerosis)
Tofersen in Non-SOD1 ALS
The goal of this clinical trial is to evaluate whether tofersen is safe and effective in adults with non-SOD1 ALS. Tofersen is currently approved by the U.S. Food and Drug Administration to treat SOD1-ALS.
- Trial name
- NCT07294144
- Testing
- Tofersen
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Washington University School of Medicine
Stroke, Parkinson Disease
PhiCube for Bilateral Upper Limb Neuromotor and Cognitive Rehabilitation in Adults
This randomized controlled pilot trial evaluates the usability and safety of PhiCube, a compact, portable, bilateral end-effector robotic device for upper limb rehabilitation, and its impact on motor and cognitive function.
- Conditions
- Stroke, Parkinson Disease, Amyotrophic Lateral Sclerosis, Spinal Cord Injuries
- Trial name
- PhiCube-Adults (NCT07865260)
- Testing
- PhiCube, Conventional rehabilitation
- Where
- 4 sites in Italy
- Volunteers
- 80 people
- Sponsor
- Istituto di Sistemi e Tecnologie Industriali Intelligenti per il Manifatturiero Avanzato
Amyotrophic Lateral Sclerosis (ALS)
Influence of Olfacto-gustatory Sensoriality on the Nutritional Status of Patients With Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterised by progressive diffuse muscular paralysis due to the inexorable loss of motor neurons in the primary motor cortex, the corticospinal tract, the…
- Trial name
- GOUSLA (NCT06608004)
- Testing
- test taking
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
ALS, ALS (Amyotrophic Lateral Sclerosis)
At-home Treatment With Cortico-spinal tDCS for Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that causes gradual muscle weakness and loss of muscle mass. It affects all muscles that control movement, speech, swallowing, and breathing.
- Trial name
- tDCS-ALS (NCT07006571)
- Testing
- Real tDCS
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- University of Trieste
Amyotrophic Lateral Sclerosis (ALS)
Impact of Robotic Glove Use on Quality of Life, Grip Strength and Fine Motor Control in ALS
The goal of this clinical trial is to determine the impact of robotic glove use on quality of life, grip strength and fine motor control in participants with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT07298486
- Testing
- Robotic Glove Use
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Nova Southeastern University
Amyotrophic Lateral Sclerosis, Charcot Disease
Therapeutic Approach of Repeated Transient Blood-brain Barrier Opening in Amyotrophic Lateral Sclerosis.
This is proof-of-concept, single-arm, single-center study to assess the safety and explore the efficacy of repeated US transient disruptions of the blood-brain barrier (BBB) in Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- Son-ALS (NCT07571486)
- Testing
- SonoCloud-4 (SC4) device
- Where
- France
- Volunteers
- 23 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Post-stroke, Parkinson Disease
Evaluation of the Impact of Virtual Park on Training Motivation in Adult Patients
The purpose of this clinical study is to evaluate the feasibility, usability, and motivational impact of VirtualPark, a virtual reality-based dual-task rehabilitation system, in adults with neurological and age-related…
- Conditions
- Post-stroke, Parkinson Disease, Amyotrophic Lateral Sclerosis, Mild Cognitive Impairment (MCI)
- Trial name
- VP_Adults (NCT07616050)
- Testing
- Dual-task training with Virtual Reality, Cycling training
- Where
- 7 sites in Italy
- Volunteers
- 70 people
- Sponsor
- Marta Mondellini
Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis
Comprehensive Analysis Platform To Understand, Remedy and Eliminate ALS
CAPTURE ALS is a long-term data and biorepository platform that will facilitate future ALS research. CAPTURE ALS will provide the standardized systems and tools necessary to collect, store, and analyze vast amounts of multimodal…
- Conditions
- Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis, Progressive Muscular Atrophy, Frontotemporal Degeneration
- Trial name
- CAPTURE ALS (NCT05204017)
- Where
- 4 sites in Canada
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Alberta
Amyotrophic Lateral Sclerosis (ALS), Emotional Distress
Resiliency Intervention for Patients With ALS and Their Care-Partners
The purpose of this study is to pilot a resiliency and coping intervention for persons recently diagnosed with Amyotrophic Lateral Sclerosis (ALS) and their primary informal caregivers.
- Trial name
- RT-ALS (NCT06968468)
- Testing
- Resilient Together ALS
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Amyotrophic Lateral Sclerosis, Movement Disorders
Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures
The goal of the study is to generate a biorepository of longitudinal biofluids-blood (plasma and serum), cerebral spinal fluid (CSF) and urine linked to genetics and longitudinal clinical information that are made available to…
- Conditions
- Amyotrophic Lateral Sclerosis, Movement Disorders, Degenerative Disorder, Motor Neuron Disease
- Trial name
- TALSLB (NCT05137665)
- Where
- 12 sites in United States, Colombia and 1 more
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Target ALS Foundation, Inc.
Amyotrophic Lateral Sclerosis
Clinical Research in ALS Study
CRiALS is an umbrella protocol through which people are recruited to participate in a range of research studies being conducted by the ALS Research Collaboration (ARC).
- Trial name
- CRiALS (NCT00136500)
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- University of Miami
Neurodegenerative Disease, Behavioral Variant Frontotemporal Dementia (bvFTD)
Tracking and Predicting How Brain Damage Spreads in Neurodegenerative Diseases
Neurodegenerative diseases, including frontotemporal lobar degeneration (FTLD) spectrum syndromes, are characterized by the accumulation of insoluble protein aggregates in the central nervous system.
- Conditions
- Neurodegenerative Disease, Behavioral Variant Frontotemporal Dementia (bvFTD), Primary Progressive Aphasia(PPA), Progressive Supranuclear Palsy(PSP)
- Trial name
- NCT07567664
- Testing
- 3 Tesla MRI without contrast medium, Blood sample for genetic analysis, Cerebrospinal fluid sampling (CSF)
- Where
- Italy
- Volunteers
- 645 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Neurodegenerative Diseases, Parkinson Disease
Neurodegenerative Diseases Progression Markers (MARKERS-NDD)
MARKERS-NDD is a prospective, observational, longitudinal study, which aims to collect data from patients affected by neurodegenerative diseases (NDD) followed longitudinally for routine examinations performed as part of normal…
- Conditions
- Neurodegenerative Diseases, Parkinson Disease, Synucleinopathies, Lewy Body Disease
- Trial name
- MARKERS-NDD (NCT06596746)
- Testing
- Observation
- Where
- Italy
- Volunteers
- 600 people
- Sponsor
- Casa di Cura San Raffaele Cassino
ALS
Amyotrophic Lateral Sclerosis (ALS) Families Project
This program provides family members of individuals with familial ALS the opportunity to contribute to research focused on learning more about why motor neuron degeneration begins and how or why it progresses.
- Trial name
- NCT03865420
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Columbia University
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Effects of Long Term Ventilation Support on the Quality of Life of ALS Patients and Their Families
Amyotrophic lateral sclerosis (ALS) is a serious rapidly progressive disease of the nervous system. The average survival from the time of diagnosis is two to three years.
- Conditions
- Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Nervous System Diseases, Spinal Cord Diseases
- Trial name
- ALS-LTMV (NCT05744310)
- Testing
- Long term mechanical ventilation support, No long term mechanical ventilation support
- Where
- 9 sites in Norway
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Haukeland University Hospital
Amyotrophic Lateral Sclerosis
Polish Version Dyspnea in Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis is a fatal disease with progressive degeneration of central and peripheral motor neurons. Weakness of pharyngeal and respiratory muscles lead to dyspnea, which is present in up to 80% of patients.
- Trial name
- NCT07178574
- Volunteers
- 120 people
- Sponsor
- Jakub Antczak
MND (Motor Neurone DIsease)
Telehealth in MND-Research (TIM-R): A Research Database for MND
The aim of this study is to implement the Telehealth in MND system as a research database allowing people with MND to take part in research and provide data remotely (TiM-Research).
- Trial name
- TIM-R (NCT07132879)
- Testing
- No intervention - Prospective cohort study
- Where
- United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- University of Sheffield
Amyotrophic Lateral Sclerosis (ALS), Mutation in the Superoxide Dismutase-1 (SOD1) Gene
First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)
This study is researching an experimental drug called ALN-SOD (called "study drug"). This study is focused on people with Amyotrophic Lateral Sclerosis (ALS) caused by a change in a gene called the Superoxide Dismutase-1 (SOD1)…
- Trial name
- GOALS (NCT06351592)
- Testing
- ALN-SOD, Diluent
- Where
- 22 sites in Australia, Belgium and 7 more
- Volunteers
- 54 people
- Sponsor
- Regeneron Pharmaceuticals
Amyotrophic Lateral Sclerosis (ALS)
Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients
The objective is to compare the efficacy and safety of masitinib in combination with riluzole versus matched placebo in combination with riluzole for the treatment of Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT07174492
- Testing
- Masitinib 4.5 mg/kg/day, Riluzole (100 mg)
- Where
- Greece
- Volunteers
- 412 people
- Sponsor
- AB Science